Presenters revealed some stunning data in coronary and peripheral revascularization during a press conference on late-breaking trials at the American College of Cardiology’s (ACC; Bethesda, Maryland) annual scientific sessions in early March. The presentations at the Ernest N. Morial Convention Center included results from the three iterations of the ARCHeR (Acculink for Revascularization of Carotids in High-Risk Patients) trial, which is focused on treatment of carotid artery disease.